47th week of 2011 patent applcation highlights part 47 |
Patent application number | Title | Published |
20110288037 | Pharmaceutical Composition for the Treatment of Pathologies Caused by the General Response of the Immune System - The present invention relates to a pharmaceutical composition consisting of amides of mono- and di-carboxylic acids and hydroxystilbenes, and may be used for the treatment of pathologies caused, sustained and/or characterised by an abnormal general response of the immune system, in both humans and animals. | 2011-11-24 |
20110288038 | HESPERIDIN-CONTAINING COMPOSITION - This invention relates to a composition that stably contains hesperidin. The present invention provides a composition containing (A) hesperidin, (B) at least one dihydric alcohol selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, and 3-methyl-1,3-butanediol, and (C) a sugar alcohol. In the composition, the decomposition of hesperidin is suppressed and hesperidin is stably contained. | 2011-11-24 |
20110288039 | Topical Ectoparasiticide Composition - A topical ectoparasiticide composition comprising an Insect Growth Regulator and at least one C | 2011-11-24 |
20110288040 | ARYL- OR HETEROARYL-SULFONYL COMPOUNDS AS ACID SECRETION INHIBITORS - The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like. | 2011-11-24 |
20110288041 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 2011-11-24 |
20110288042 | STABLE HIGHLY PURE AZACITIDINE AND PREPARATION METHODS THEREFOR - Disclosed herein are methods of obtaining highly pure 5-azacytidine, which contains minimal amounts of degradation impurities and methods of assessing the impurity profile of the degradation of cytidine analogues, such as 5-azacytidine | 2011-11-24 |
20110288043 | MAINTENANCE OF PLATELET INHIBITION DURING ANTIPLATELET THERAPY - A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyhdine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects diagnosed with symptoms such as stable or unstable angina, vascular ischemic events, atherosclerosis, acute coronary syndrome, as well as STEMi or N-STEMI. The described method can also be used for patients having previously received a stent, such as a bare metal stent or a drug-eluting stent, and the treatment or prevention of stent thrombosis. The method can be used prior to, during, or after an invasive procedure such as coronary artery bypass grafting, percutaneous coronary intervention, or other genera! surgical procedure. | 2011-11-24 |
20110288044 | Modulation of sodium channels by nicotinamide adenine dinucleotide - The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD | 2011-11-24 |
20110288045 | WET GRANULATION OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ - The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known degradation products. | 2011-11-24 |
20110288046 | ANALYSIS OF SULFATED POLYSACCHRIDES - The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described. | 2011-11-24 |
20110288047 | PROCESS FOR THE PURIFICATION OF HEPARAN SULFATE AND USE THEREOF IN COSMETOLOGICAL AND DERMATOLOGICAL PREPARATIONS - The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin by using conditions which result in selective desorption of hepar an sulfate. The cosmetological and dermatological compositions according to the invention show, inter alia, anti-age, lenitive, and whitening effect. | 2011-11-24 |
20110288048 | PROMOTER FOR HARD TISSUE FORMATION - The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation promoter, a cell differentiation inducer and a cellular alkaline phosphatase activity reinforcing agent comprising, as an active ingredient, a glycosaminoglycan or a salt thereof that keeps sulfate group and has the characteristics of the following (1) and (2): (1) a basic structure is a disaccharide repeating structure consisting of a hexuronic acid residue and a glucosamine residue, (2) one or less of the position among a 2-position hydroxyl group of a hexuronic acid residue, a 6-position hydroxyl group of a glucosamine residue and a 2-position amino group of the glucosamine residue in the basic structure of the aforementioned (1) does not have the sulfate group. In this connection, it is preferable that the hexuronic acid residue is a glucuronic acid residue or an iduronic acid residue. | 2011-11-24 |
20110288049 | Compositions, Systems, and/or Methods Involving Chlorine Dioxide ("ClO2") - Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. The concentration of chlorine dioxide in said solid form is greater than approximately 5.8 percent by weight. Certain exemplary embodiments can provide a method comprising forming a solid complex comprising chlorine dioxide and cyclodextrin, wherein a concentration of chlorine dioxide in the solid complex is greater than 5.8 percent by weight. | 2011-11-24 |
20110288050 | PROTEIN PHOSPHATASE INHIBITOR - Provided is a novel protein phosphatase inhibitor. The protein phosphatase inhibitor contains, as an active ingredient, a silicon compound represented by the following general formula (1) or a salt thereof, wherein R | 2011-11-24 |
20110288051 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS - Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: | 2011-11-24 |
20110288052 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME - The class compounds of the present invention may be represented by Formula (I), wherein X may be O, S, or N. R | 2011-11-24 |
20110288053 | ANTIVIRAL PHOSPHONATE ANALOGS - The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2011-11-24 |
20110288054 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. | 2011-11-24 |
20110288055 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS - This invention relates to pharmaceutically acceptable amphiphilic antioxidant compounds, compositions and dosage forms comprising said compounds, and methods and uses reliant on said compounds. The exemplified compounds are all mitoquinone derivatives, being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives. The compounds, compositions, dosage forms, uses and methods are useful in, for example, the treatment of diseases or conditions associated with oxidative stress. | 2011-11-24 |
20110288056 | Once daily formulations of tetracyclines - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 2011-11-24 |
20110288057 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS - The invention relates to the use of and mainly novel compounds of the formula I | 2011-11-24 |
20110288058 | Methods for Preventing or Reducing Colon Carcinogenesis - The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient in need thereof an antioxidant effective amount of a compound represented by formula I, IIa or IIb as disclosed herein. | 2011-11-24 |
20110288059 | NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE THEREFOR - Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder in a subject, methods for ameliorating a symptom of schizophrenia, schizoaffective disorder, or other psychotic disorder in a subject, methods for ameliorating a symptom of a depressive disorder in a subject, methods for ameliorating a symptom of bipolar disorder in a subject, methods for ameliorating a symptom of post-traumatic stress disorder or other anxiety disorder in a subject, methods for predicting a predisposition to suicide, suicidal ideation, suicidal behavior, or a combination thereof in a subject, methods for ameliorating a symptom of a pain disorder in a subject, methods for ameliorating a neurodegenerative disorder in a subject, methods for ameliorating a symptom of traumatic brain injury in a subject, methods for ameliorating a sleep disorder in a subject, and methods for improving cognitive functioning in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof. | 2011-11-24 |
20110288060 | APPARATUS AND PROCESS FOR PRODUCING CRYSTALS - This invention provides an oscillating baffled reactor apparatus for preparing crystalline particles of at least one substance comprising: a reactor vessel; means for supplying a first flowing stream; means for oscillating fluid within the reactor vessel; a plurality of baffles; source of ultrasonic radiation; and means for collecting said particles. | 2011-11-24 |
20110288061 | Triterpenoid derivatives, benzenoid derivatives and pharmaceutical compositions containing the same - The present invention relates to triterpenoid derivatives, benzenoid derivatives, and pharmaceutical compositions containing the same for treating cancers or inflammatory symptoms. According to the present invention, the triterpenoid derivatives and the benzenoid derivatives are respectively represented by the following formulas (I) and (II): | 2011-11-24 |
20110288062 | Biodegradable polymer system - A polymer system useful for in vivo delivery of a therapeutic agent is provided. The polymer system comprises a biocompatible biodegradable polymeric backbone that is capable of a reversible stimuli-induced transition from liquid to gel. | 2011-11-24 |
20110288063 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS - A compound of formula (I) or formula (Ia) | 2011-11-24 |
20110288064 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL - The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit. | 2011-11-24 |
20110288065 | AMINOPYRAZINE DERIVATIVE AND MEDICINE - The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutical acceptable salt of the compound. | 2011-11-24 |
20110288066 | PHENOXY ACETIC ACID DERIVATIVES - The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses. | 2011-11-24 |
20110288067 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 2011-11-24 |
20110288068 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES - The present invention provides a compound of Formula I or Formula II: | 2011-11-24 |
20110288069 | Benzodiazepine and Pyridodiazepine Derivatives - The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) | 2011-11-24 |
20110288070 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE - This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein (I), Q, J, L and Z are as defined in the specification. | 2011-11-24 |
20110288071 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER - The present invention encompasses compounds of general formula (1) wherein A, B, X, R | 2011-11-24 |
20110288072 | Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction - Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-trien-7-yl]-methyl }-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5 -tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction. | 2011-11-24 |
20110288073 | Alpha-Aminocyclolactam Ligands for G-protein Coupled Receptors, and Methods of Using Same - The invention relates to the generation of a library of compounds enriched in agonist and antagonists for members of the G-protein coupled class of receptors (GPCRs). | 2011-11-24 |
20110288074 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF - The present invention provides new compounds with high affinity for adenosine A | 2011-11-24 |
20110288075 | Pyridazinone Derivatives - The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders. | 2011-11-24 |
20110288076 | Sphingosine-1-Phosphate Receptor Antagonists - This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particularly, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists. | 2011-11-24 |
20110288077 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES - This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α combinations thereof. | 2011-11-24 |
20110288078 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS - This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use. | 2011-11-24 |
20110288079 | Tannate Compositions, Methods of Making and Methods of Use - Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions. | 2011-11-24 |
20110288080 | Nitrofuran Compounds for the Treatment of Cancer and Angiogenesis - The invention is directed to the synthesis and use of nitrofuran compounds, especially Nifurtimox, as medicaments to treat cancer, especially neuroblastoma, and to inhibit angiogenesis. The invention also provides compositions, unit dosage forms, and kits comprising the compounds. | 2011-11-24 |
20110288081 | PYRIMIDINE COMPOUNDS AND USES THEREOF - This invention features pyrimidine compounds of formula (I): | 2011-11-24 |
20110288082 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE - Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof | 2011-11-24 |
20110288083 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE - The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first model comprising PERK active domains, where the said active domains are selected from the group consisting of the peptide spanning from amino acid residue Asp144 to amino acid residue Ser191 of SEQ ID NO: 1 and a peptide comprising the amino acid residue at position 7 of SEQ ID NO: 1, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying the compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for inhibiting PERK. The present invention further relates to compounds that can be used for inhibition of PERK, for example human PERK, and methods related to treatment of PERK-mediated diseases. | 2011-11-24 |
20110288084 | [4-( 1-AMINO-ETHYL) - CYCLOHEXYL ] - METHYL - AMINES AS ANTIBACTERIALS - The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation. | 2011-11-24 |
20110288085 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS - A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase. | 2011-11-24 |
20110288086 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF - At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, | 2011-11-24 |
20110288087 | FUSED RING COMPOUND AND USE THEREOF - Provided is a novel compound represented by the following formula | 2011-11-24 |
20110288088 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS - Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer. | 2011-11-24 |
20110288089 | INSECTICIDAL COMPOUNDS - A compound of Formula (I): wherein A | 2011-11-24 |
20110288090 | Inhibitors of AKT Activity - The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 2011-11-24 |
20110288091 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF - The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds. | 2011-11-24 |
20110288092 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof - Disclosed are methods of treating hyperproliferative disorders, method of treating inflammatory disorders, and methods of inhibiting MEK activity in a mammal, comprising administering an effective amount of one or more compounds of the Formula V | 2011-11-24 |
20110288093 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives - The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of chloride channel by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof | 2011-11-24 |
20110288094 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY - Compounds of the formula | 2011-11-24 |
20110288095 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2011-11-24 |
20110288096 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 2011-11-24 |
20110288097 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 2011-11-24 |
20110288098 | NOVEL COMPOUNDS - This invention relates to imidazopyrazine substituted piperidine derivatives and their use as pharmaceuticals. | 2011-11-24 |
20110288099 | COMPOSITIONS WITH REDUCED HEPATOTOXICITY - Pharmaceutical compositions of hepatotoxic compounds are provided in which the hepatotoxicity of the compounds is mitigated by including quantities of nicotinamide and methionine in the composition. Folic acid also can be included to further mitigate the hepatotoxic effects. The hepatotoxic compounds can include acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanozole, divalproex sodium, and valproic acid. | 2011-11-24 |
20110288100 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses a compound of formula: | 2011-11-24 |
20110288101 | SURGICAL COMPOSITIONS CONTAINING SIGMA-RECEPTOR AGONISTS - One aspect of the present invention relates to aqueous surgical compositions comprising a sigma-1 receptor agonist. Another aspect of the present invention relates to methods of irrigating ocular tissues during an ophthalmic surgical procedure such as cataract surgery. Such methods comprise bathing the ocular tissues with a composition comprising a sigma-1 receptor agonist. | 2011-11-24 |
20110288102 | IL-8 BIOMARKER FOR MONITORING CANCER TREATMENT - The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor. | 2011-11-24 |
20110288103 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES - The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of calcium activated chloride echannel (CaCC) by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions thereof, thereby treating the disease. | 2011-11-24 |
20110288104 | Beta-3 receptor ligands and their use in therapy - The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of the beta-3 adrenergic receptor as medicaments. | 2011-11-24 |
20110288105 | ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA - The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in Parkinson's patients, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof. | 2011-11-24 |
20110288106 | ADENINE RECEPTOR LIGANDS - The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs. | 2011-11-24 |
20110288107 | TOPICAL FORMULATION FOR A JAK INHIBITOR - This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. | 2011-11-24 |
20110288108 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF - The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells. | 2011-11-24 |
20110288109 | NEW COMPOUNDS - The present invention includes compounds of general Formula (1), wherein A, X, R | 2011-11-24 |
20110288110 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL - The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a HMG-CoA reductase inhibitor (for example simvastatin or atorvastatin). Co-administration of the MTP inhibitor with the HMG-CoA reductase inhibitor produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit. | 2011-11-24 |
20110288111 | INHIBITION OF INFLUENZA M2 PROTON CHANNEL - Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. | 2011-11-24 |
20110288112 | Method of Providing Sustained Analgesia With Buprenorphine - A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. | 2011-11-24 |
20110288113 | METHOD TO REDUCE OR ELMINATE THE USE BY A PATIENT OF A TOLERANCE-INDUCING PHARAMACOLOGICAL AGENT - A multiple total daily dose regimen is developed in order to decrease the use by a patient of a tolerance-inducing pharmacological agent. In one example, the method reduces or phases out altogether a patient's chronic use of opioid drugs by use of a successive reduction of the total daily dose of an opioid drug in sub-therapeutic decrements over the course of 3-7 days per therapeutic dose. | 2011-11-24 |
20110288114 | COMPOSITIONS FOR THE TREATMENT OF FIBROTIC DISEASES OR CONDITIONS - A method of treating a fibrotic disease or condition in a patient comprising administering noscapine and a pharmaceutical carrier to said patient. | 2011-11-24 |
20110288115 | TREATMENT OF VAGALLY-MEDIATED SPECTRUM DISORDERS - The present invention provides a method of treatment of a vagally-mediated spectrum disorder, comprising administering an effective amount of a 5-HT | 2011-11-24 |
20110288116 | IAP INHIBITORS - The present invention describes compounds of the following formula: processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. The compounds of the present invention inhibit IAPs (inhibitors of apoptosis proteins) and thus are useful in the treatment of cancer, autoimmune diseases and other disorders where a defect in apoptosis is implicated. | 2011-11-24 |
20110288117 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 2011-11-24 |
20110288118 | PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN - Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer. | 2011-11-24 |
20110288119 | Low dose - prov (alpha 7-EVP) - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition. | 2011-11-24 |
20110288120 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - Isoquinolone derivatives of the general formula (I) are NK3 antagonists. | 2011-11-24 |
20110288121 | Processes for Producing Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to the process for producing modulators of cystic fibrosis transmembrane conductance regulator (CFTR). | 2011-11-24 |
20110288122 | Pharmaceutical Compositions and Administrations Thereof - The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. | 2011-11-24 |
20110288123 | FORMULATIONS FOR THE TREATMENT OF ACUTE HERPES ZOSTER PAIN - The present invention provides compositions and methods that are useful for treatment of pain associated with acute herpes zoster. The aqueous compositions are non-stinging and non-irritating. | 2011-11-24 |
20110288124 | COMPOSITIONS AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE - The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive, and about 30 to 50 wt % silicone adhesive and wherein said methylphenidate is delivered to a subject in need thereof such that the plasma concentration of methylphenidate increases over a period of about 6-16 hours, and more preferably over a period of about 6-12 hours followed by a steady decrease in plasma concentration of methylphenidate. | 2011-11-24 |
20110288125 | NOVEL USE OF PIPERINE - The present invention is related to novel use of piperine, and more specifically, it is related to a pharmaceutical or food composition for preventing and treating obesity comprising piperine or a salt thereof as an active ingredient. The present invention is related to novel use of piperine, and it provides a pharmaceutical or food composition for preventing and treating obesity comprising piperine or a salt thereof as an active ingredient. The composition comprising piperine of the present disclosure is effective on suppression of abdominal fat accumulation and body weight loss. Therefore, the composition can be effectively used to prevent and treat obesity. | 2011-11-24 |
20110288126 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES - This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent. | 2011-11-24 |
20110288127 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 2011-11-24 |
20110288128 | Oral Transmucosal Administration of Sufentanil - Compositions and methods for administration of sufentanil-containing drug formulations to the oral mucosa of a subject are disclosed. | 2011-11-24 |
20110288129 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 2011-11-24 |
20110288130 | BACTERIAL THIOREDOXIN REDUCTASE INHIBITORS AND METHODS FOR USE THEREOF - The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of | 2011-11-24 |
20110288131 | INSECTICIDAL COMPOUNDS - A compound of formula (I) wherein A | 2011-11-24 |
20110288132 | Nicotine and Cocoa Powder Compositions - The present invention relates to a nicotine-containing pharmaceutical composition and methods of using the composition in therapies, such as nicotine replacement therapy. | 2011-11-24 |
20110288133 | HISTONE DEACETYLASE INHIBITORS - This invention relates to novel Histone deacetylases inhibitors. Also disclosed is a method for treating mucositis or cancer with these inhibitors. | 2011-11-24 |
20110288134 | COMPOSITION AND METHOD FOR TREATING FIBROSIS - The present invention relates, in general, to fibroproliferative disorders, and, in particular, to a method of treating, preventing or reducing fibroproliferative disorders by administering to a mammal in need a composition comprising pharmacologically effective doses of a cytokine modifier, such as tranilast or pirfenidone, and an anti-oxidant which is a precursor of glutathione, such as N-acetyl-cysteine, or their pharmaceutically acceptable derivatives, salts, metabolites, or structural or functional analogues thereof. | 2011-11-24 |
20110288135 | Fast Dissolving Tablet - The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided. | 2011-11-24 |
20110288136 | FLAVIVIRUS INHIBITION BY SULTAMS AND RELATED COMPOUNDS - Disclosed herein are compounds, compositions and methods for treating or ameliorating flavivirus infections. This is particularly important because the present disclosure provides methods for treating flavivirus infections for which there is no effective vaccine. | 2011-11-24 |